HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Carlos H.R. Boasquevisque Joel D. Cooper G. Alexander Patterson Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagahiro, I. Articles by Patterson, G. A. Search for Related Content PubMed PubMed Citation Articles by Nagahiro, I. Articles by Patterson, G. A.

Ann Thorac Surg 1998;66:351-355
© 1998 The Society of Thoracic Surgeons

---

Original articles: general thoracic

Recombinant kunitz protease inhibitor ameliorates reperfusion injury in rat lung transplantation

^a Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
^b Scios Inc, Sunnyvale, California, USA

Address reprint requests to Dr Patterson, Division of Cardiothoracic Surgery, Washington University School of Medicine, 3108 Queeny Tower, One Barnes Hospital Plaza, St. Louis, MO 63110

Presented at the Forty-fourth Annual Meeting of the Southern Thoracic Surgical Association, Naples, FL, Nov 6–8, 1997.

Background. Recombinant Kunitz protease inhibitor (rKPI-BG022) is more homologous to human Kunitz protease inhibitor than is aprotinin. Because aprotinin has been reported to inhibit free radicals, we hypothesized that rKPI would ameliorate reperfusion injury caused by free radicals. We examined its effect and the timing of administration in an in vivo rat lung transplantation model.

Methods. All lungs were flushed with low-potassium dextran–1% glucose solution and stored for 24 hours at 4°C, then orthotopic left lung transplantations were performed. Rats were divided into 4 groups (n = 6) as follows: group 1 served as control; in Group 2, rKPI was added to the flush solution (10 µmol/L); in group 3, rKPI (5 mg/kg) was administered intravenously to the recipient just after reperfusion; and in group 4, rKPI was added to the flush solution (10 µmol/L) and rKPI (5 mg/kg) was administered intravenously to the recipient just after reperfusion. Twenty-four hours after transplantation, the right main pulmonary artery and right main bronchus were ligated, and the rats were ventilated with 100% O₂ for 5 minutes. Peak airway pressure, blood gas analysis, serum lipid peroxide level, tissue myeloperoxidase activity, and wet-dry weight ratio were measured.

Results. The partial oxygen tension values of group 2 were higher than those of groups 1 and 4 (groups 1, 2, and 4: 104.8 ± 15.8, 245.1 ± 49.0, 101.4 ± 4.5 mm Hg, respectively; p < 0.01). The partial carbon dioxide tension values of groups 3 and 4 were lower than those of group 1 (groups 1, 3, and 4: 74.5 ± 5.7, 42.0 ± 11.0, 46.0 ± 8.4 mm Hg, respectively; p < 0.05). Peak airway pressures were lower in groups 2 and 3 than in groups 1 and 4 (groups 1, 2, 3, and 4: 22.5 ± 0.5, 18.2 ± 0.5, 19.2 ± 0.8, 22.5 ± 1.1 mm Hg; p < 0.01). Serum lipid peroxide levels in groups 2 and 3 were lower than those of groups 1 and 4 (groups 1, 2, 3, and 4: 0.793 ± 0.037, 0.577 ± 0.069, 0.560 ± 0.029, and 0.785 ± 0.053 nmol/mL, respectively; groups 2 and 3 vs group 1, and group 3 vs group 4: p < 0.01; group 2 vs group 4: p < 0.05). There were no differences in wet-dry weight ratio and tissue myeloperoxidase activity between the groups.

Conclusion. Recombinant Kunitz protease inhibitor ameliorates reperfusion injury caused by free radicals in an in vivo rat lung transplantation model. Administration of rKPI through the flush solution and intravenous injection after reperfusion were effective separately, but the combination of the two administrations was not effective.

This article has been cited by other articles:

				K. Durgut, K. Hosgor, N. Gormus, U. Ozergin, and H. Solak The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs Perfusion, March 1, 2004; 19(2): 101 - 106. [Abstract] [PDF]

				C. E. Reed General thoracic surgery and the Southern Thoracic Surgical Association: the second 25 years Ann. Thorac. Surg., November 1, 2003; 76(90050): S14 - 16. [Full Text] [PDF]

				S. Eren, H. Esme, A. E. Balci, O. Cakir, H. Buyukbayram, M. N. Eren, L. Erdinc, and O. Satici The effect of aprotinin on ischemia-reperfusion injury in an in situ normothermic ischemic lung model Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 60 - 65. [Abstract] [Full Text] [PDF]

				A. Rahman, B. Ustunda, O. Burma, I. H. Ozercan, A. Cekirdekci, and M. K. Bayar Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 583 - 588. [Abstract] [Full Text] [PDF]

				M. A. Mathias, C. G. Tribble, J. F. Dietz, R. P. Nguyen, K. S. Shockey, J. A. Kern, and I. L. Kron Aprotinin improves pulmonary function during reperfusion in an isolated lung model Ann. Thorac. Surg., November 1, 2000; 70(5): 1671 - 1674. [Abstract] [Full Text] [PDF]

				M. L. Barr Reply Ann. Thorac. Surg., May 1, 1999; 67(5): 1539 - 1540. [Full Text] [PDF]

				T. Wittwer, T. Wahlers, S. Elki, and A. Haverich Aprotinin-enhanced lung preservation solutions: is it worthwhile Ann. Thorac. Surg., May 1, 1999; 67(5): 1538 - 1539. [Full Text] [PDF]